LAUSR

Background and Aims: To describe the epidemiological characteristics of patients admitted for COVID19 from March 2020 to January 2021 in our hospital under treatment with statins. Methods: Retrospective descriptive study of a cohort of all patients with COVID-19 admitted to the Infectious Diseases Service at Hospital Infanta Elena from March 2020 to January 2021. Those patients with SARS CoV2 infection documented by PCR of the nasopharyngeal exudate and radiological involvement with risk factors and statin treatment were analyzed. Among these factors are: age over 60 years, chronic cardiovascular and respiratory diseases, type 2 Diabetes Mellitus (DM 2), chronic kidney disease and oncohematological diseases. Results: A cohort of 65 patients was analyzed, of which 23.08% were on statin treatment, with a mean age of 74 + 10.48 sd years, of which 66.7% were men and 33.3% were women. Of the patients taking statins, 86% were smokers and 13.13% were non-smokers. Regarding the rest of the cardiovascular factors, 93.3% were hypertensive, 40% type 2 DM, 20% had a history of coronary disease, 33.3% heart failure, 6.7% COPD, 13.3% chronic kidney disease and 6.7% active neoplasia. In the group that did not take statins, there were 5 deaths (12.2%) and had a median of 10 days of admission, compared to 3 deaths (21.4%) and 11 days of admission in the group that took statins. Conclusions: In our healthcare setting, patients undergoing treatment with statins were admitted less, had less mortality, and their most frequent comorbidities were hypertension, DM2, heart failure and coronary disease.